CoChat

Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs

Open access
Brady, Rachel V., Thamm, Douglas H. · 2023 · Frontiers in Immunology

The DOI matches its Crossref record; 330 of the 330 references it cites were found in a registry or an index.

Abstract

Macrophages are ancient, phagocytic immune cells thought to have their origins 500 million years ago in metazoan phylogeny. The understanding of macrophages has evolved to encompass their foundational roles in development, homeostasis, tissue repair, inflammation, and immunity. Notably, macrophages display high plasticity in response to environmental cues, capable of a strikingly wide variety of dynamic gene signatures and phenotypes. Macrophages are also involved in many pathological states including neural disease, asthma, liver disease, heart disease, cancer, and others. In cancer, most tumor-associated immune cells are macrophages, coined tumor-associated macrophages (TAMs). While some TAMs can display anti-tumor properties such as phagocytizing tumor cells and orchestrating an immune response, most macrophages in the tumor microenvironment are immunosuppressive and pro-tumorigenic. Macrophages have been implicated in all stages of cancer. Therefore, interest in manipulating macrophages as a therapeutic strategy against cancer developed as early as the 1970s. Companion dogs are a strong comparative immuno-oncology model for people due to documented similarities in the immune system and spontaneous cancers between the species. Data from clinical trials in humans and dogs can be leveraged to further scientific advancements that benefit both species. This review aims to provide a summary of the current state of knowledge on macrophages in general, and an in-depth review of macrophages as a therapeutic strategy against cancer in humans and companion dogs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1176807

Cites

330 of 330 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Simplified ontogeny of macrophages. In several waves of primitive hematopoiesis stemming initially from the embryonic yolk sac, erythro-myeloid progenitors differentiate into primitive macrophages and fetal monocytes that eventually become adult microglia and TRMs, respectively. These progenitors also seed the fetal liver, along with pre-HSCs and HSCs from the embryo, yolk sac, and placenta. The fetal liver, the major site of hematopoiesis, subsequently produces liver monocytes, which likely contribute perinatally to macrophage pools in the adult. HSCs, after maturing in the fetal liver, also seed the fetal bone marrow and spleen. In the adult, HSCs from the bone marrow differentiate through several monocyte precursors before being released into the blood as monocytes. These cells are recruited by inflammation and injury in the tissue, and terminally differentiate into MDMS. The spleen also holds a pool of monocytes that can be mobilized when needed. TRMs will be replaced to varying degrees in different tissues by MDMs in the adult. Many of these steps are areas of ongoing research and debate in murine and human models; similar fate-mapping studies have not been undertaken in dogs. For more detail, focused reviews are recommended (34, 40–42). Created with BioRender.com. TRMs, tissue-resident macrophages; HSCs, hematopoietic stem cells; MDMs, monocyte-derived macrophages.
Figure 1 Simplified ontogeny of macrophages. In several waves of primitive hematopoiesis stemming initially from the embryonic yolk sac, erythro-myeloid progenitors differentiate into primitive macrophages and fetal monocytes that eventually become adult microglia and TRMs, respectively. These progenitors also seed the fetal liver, along with pre-HSCs and HSCs from the embryo, yolk sac, and placenta. The fetal liver, the major site of hematopoiesis, subsequently produces liver monocytes, which likely contribute perinatally to macrophage pools in the adult. HSCs, after maturing in the fetal liver, also seed the fetal bone marrow and spleen. In the adult, HSCs from the bone marrow differentiate through several monocyte precursors before being released into the blood as monocytes. These cells are recruited by inflammation and injury in the tissue, and terminally differentiate into MDMS. The spleen also holds a pool of monocytes that can be mobilized when needed. TRMs will be replaced to varying degrees in different tissues by MDMs in the adult. Many of these steps are areas of ongoing research and debate in murine and human models; similar fate-mapping studies have not been undertaken in dogs. For more detail, focused reviews are recommended (34, 40–42). Created with BioRender.com. TRMs, tissue-resident macrophages; HSCs, hematopoietic stem cells; MDMs, monocyte-derived macrophages.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Macewen EG Kurzman ID Helfand S Vail D London C Kisseberth W. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: A progress review*. J Drug Target (1994) 2: 391–6. doi: 10.3109/10611869408996814 7704483 · DOI · Paper page
  2. Gordon SR Maute RL Dulken BW Hutter G George BM McCracken MN. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature (2017) 545: 495. doi: 10.1038/NATURE22396 28514441 PMC5931375 · DOI · Paper page

Cited by

See all 35

Metadata

Authors
Brady, R. V., & Thamm, D. H.
Affiliations
Colorado State University (US)
Corresponding author
Thamm, Douglas H.
Venue
Frontiers in Immunology
Published
2023-04-05
Volume
14
Pages
1176807-1176807
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4362637748
Cited by
35
References
329
Citations by year
2026: 11 · 2025: 8 · 2024: 14 · 2023: 2
FWCI
0.97
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • American Kennel Club Canine Health Foundation (03033-E)
  • Morris Animal Foundation (D22CA-500)
  • National Institutes of Health (2T32OD010437-21)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
tumor-associated macrophages, macrophage plasticity, tumor microenvironment, immunosuppression, pet dogs, dogs as cancer models, macrophage phenotype, macrophage origin
MeSH terms
Tumor-Associated Macrophages, Animals, Dogs, Humans, Macrophages, Neoplasms, Prognosis, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.